JAGX Stock Forecast: Jaguar Health, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.23

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 50 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$3.0M
Ticker Nerd rank
50/ 100
Median analyst target
$263
Analysts covering
—
Revenue$1.2M−58.9% y/y
Operating income−$7.6M
Net income−$12.8M
Free cash flow−$5.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Jaguar Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
50/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
99
Growth
95
Quality
53
Issuance
50
Momentum
27
Revisions
20
Value
10
Volatility
6

Accruals (99): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (6): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

JAGX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on JAGX, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 May 2025First BerlinInitiatesBuy$60
7 July 2021Cantor FitzgeraldInitiatesOverweight$5.00
25 Nov 2020Aegis CapitalInitiatesBuy—
25 Nov 2020H.C. WainwrightReiteratesBuy—
25 Nov 2020Ladenburg ThalmannInitiatesBuy—
25 Nov 2020Rodman & RenshawInitiatesBuy—
18 Nov 2019H.C. WainwrightReiteratesBuy—
18 Nov 2019HC Wainwright & Co.ReiteratesBuy$10 → $3.00
12 Sept 2019Ladenburg ThalmannInitiatesBuy—
11 July 2017Rodman & RenshawInitiatesBuy—
12 Nov 2015Aegis CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

JAGX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

JAGX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
0.1×

Cheaper than 94% of US stocks

Price / book
0.0×

Cheaper than 99% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
15.8%

Higher than 15% of US stocks

Operating margin
−88.2%

Higher than 15% of US stocks

Net margin
—
Returns & dividend
Return on equity
−288.1%

Higher than 5% of US stocks

Return on assets
−36.4%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Jaguar Health, Inc. has a market value of $3.0M.

  • Revenue in the twelve months to 30 June 2026: $27.8M. The latest quarter shrank 58.9% year on year.

  • Net income over the same four quarters: −$36.9M, a −132.9% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$6.7M.

  • Shares outstanding: 4.9M.

  • Jaguar Health, Inc. employs 47 people — $591K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

JAGX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
JAGXJaguar Health, Inc.$3.0M50
CELZCreative Medical Technology Holdings, Inc.$3.1M16
SKYESkye Bioscience, Inc.$3.1M50
AZTRAzitra, Inc.$3.1M26
NRSNNeurosense Therapeutics Ltd.$3.2M3
KPRXKiora Pharmaceuticals, Inc.$3.2M60
APREAprea Therapeutics, Inc.$3.2M20

Take a look at JAGX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Jaguar Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about JAGX

How does Ticker Nerd's model rank JAGX?

As at 21 Nov 2026, Jaguar Health, Inc. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (99 of 100).

What is the JAGX stock forecast for 2030?

No analyst covering Jaguar Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JAGX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $263 to $263 over the next 12 months.

What does Jaguar Health, Inc. do?

Jaguar Health, Inc. is a commercial-stage pharmaceuticals company focused on developing and commercializing plant-based gastrointestinal products for humans and animals. Its current business is organized around two segments, Human Health and Animal Health, covering prescription and non-prescription products for conditions such as chronic diarrhea, bowel urgency, and related gastrointestinal distress.

Company

About Jaguar Health, Inc.

Jaguar Health, Inc. is a commercial-stage pharmaceuticals company focused on developing and commercializing plant-based gastrointestinal products for humans and animals. Its current business is organized around two segments, Human Health and Animal Health, covering prescription and non-prescription products for conditions such as chronic diarrhea, bowel urgency, and related gastrointestinal distress. The company’s human portfolio includes therapies for HIV-related diarrhea and other gastrointestinal indications, while its animal health activities target companion and production animals with digestive health needs. Jaguar Health also works through its subsidiaries to support proprietary products derived from sustainably sourced botanical ingredients. Headquartered in San Francisco, California, Jaguar Health plays a specialized role in the pharmaceutical market by addressing gastrointestinal disorders across both human and veterinary care.

CEO Ms. Lisa A. Conte · 47 employees · United States · https://jaguar.health